Novo Nordisk's Failed Heart Drug Trial Sets Up a High-Stakes Reckoning With Investors
Published on 08/03/2026 at 05:42 | Redaktion boerse-global.de
The Danish pharmaceutical giant enters its most consequential week of the year nursing a fresh wound. Novo Nordisk's shares tumbled 8.48 percent on Friday to close at EUR 40.90 — its worst session in the European healthcare sector — after the company revealed that its inflammation drug Ziltivekimab had failed a pivotal cardiovascular study. The setback leaves the stock trading 25.45 percent below its 52-week high of EUR 54.86, a level reached in late January.
A Missed Primary Endpoint and a Questionable Safety Signal
The Phase 3 ZEUS trial enrolled 6,376 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and elevated inflammatory markers. While Ziltivekimab successfully lowered inflammatory biomarkers including hsCRP and IL-6, the antibody failed to deliver on its primary objective: with a hazard ratio of 0.99 (95 percent confidence interval 0.88 to 1.11), it produced no measurable reduction in cardiovascular events versus placebo. Compounding the disappointment, serious infections occurred more frequently among patients receiving the drug, although mortality rates showed no difference between the groups.
Investors on both sides of the Atlantic reacted sharply. US-listed shares fell 8.6 percent on the Nasdaq, while Copenhagen-listed stock dropped roughly 7.5 percent in early trading.
The Corvidia Bet Turns Sour
The failed trial strikes at one of Novo Nordisk's more significant acquisitions. The company secured rights to Ziltivekimab in 2020 through its takeover of Corvidia Therapeutics, paying USD 725 million upfront with a total deal value of up to USD 2.1 billion contingent on milestone achievements. Following the ZEUS disappointment, the company will record a non-cash impairment charge in the third quarter of 2026, which the analysis portal AktienSensor estimates at approximately EUR 120 million.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The writedown does not alter the company's current-year outlook. Novo Nordisk reaffirmed its 2026 guidance for adjusted operating profit of EUR 8.5 billion to EUR 9.0 billion, pointing to cash reserves of roughly EUR 15 billion as a buffer.
Analysts See Overreaction, But Technicals Tell a Cautious Story
Not all market observers view Friday's sell-off as the final verdict. Jefferies characterized the ZEUS outcome as strategically negative for the company's inflammation pipeline but deemed the intensity of the share price reaction excessive. Citi broadly shares that assessment. The technical picture lends some support to this measured view: the 14-day RSI sits at 41.8, indicating the stock is approaching oversold territory without having entered it. Still, the shares have lost 5.81 percent over the past 30 days and are down 7.10 percent year-to-date.
A Second Blow and a Legal Cloud
The ZEUS failure marks the second major clinical disappointment for Novo Nordisk this year, following the setback surrounding its obesity candidate CagriSema. That earlier stumble has also spawned legal complications: a US judge ruled that the company must face a shareholder lawsuit related to CagriSema.
What Wednesday's Numbers Must Deliver
All eyes now turn to Wednesday, August 5, when Novo Nordisk releases its first-half results for 2026. The report lands at 7:30 AM CET, with a management conference call following at 1:00 PM. The market's focus will center on the growth trajectory of the GLP-1 portfolio, particularly Wegovy and Ozempic. The oral Wegovy tablet, which saw strong demand after its launch earlier this year, is expected to generate considerable discussion.
Investors also want clarity on production capacity. The company has wrestled with supply constraints for months and continues integrating additional manufacturing sites to meet global demand. The earnings date carries added weight because rival Eli Lilly also reports quarterly results on August 5, sharpening the competitive picture in the obesity drug market — Lilly's oral product Foundayo (orforglipron) has been gaining meaningful traction since its April 2026 launch.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Analysts will scrutinize the 2026 annual guidance closely. Novo Nordisk has already characterized the current year as a potential "trough," with operating profit expected to contract by 4 to 12 percent on a currency-adjusted basis. Any deviation from that trajectory could move the shares. New late-stage pipeline data, particularly around the CagriSema combination therapy, will also be in focus.
The Technical Line in the Sand
Friday's decline has pushed the stock into precarious chart territory. At EUR 40.90, the shares sit just above their 200-day moving average of EUR 40.35. Market observers view defending this level as critical to avoiding a further technical downtrend.
Glimmers of Hope Beyond the Immediate Damage
For investors looking further ahead, two additional trials with Ziltivekimab remain ongoing: HERMES in heart failure patients and ARTEMIS following heart attacks. Results are expected in the first half of 2027. Whether they can restore confidence in the company's cardiovascular strategy that ZEUS has shaken remains an open question. In the near term, the third-quarter impairment charge stands as the most concrete consequence of the failed program, while next week's half-year figures — alongside macroeconomic data such as US services PMI and employment numbers — will offer the clearest read on the company's operational health and its ability to rebuild investor trust.
Ad
Novo Nordisk Stock: New Analysis - 3 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
